Article
Gastroenterology & Hepatology
Delphine Ley, Ariane Leroyer, Claire Dupont, Helene Sarter, Valerie Bertrand, Claire Spyckerelle, Nathalie Guillon, Pauline Wils, Guillaume Savoye, Dominique Turck, Corinne Gower-Rousseau, Mathurin Fumery, Epimad Grp
Summary: This study evaluated the impact of immunosuppressants and antitumor necrosis factor on long-term outcomes of pediatric-onset ulcerative colitis in a large population-based cohort. The results showed a significant decline in the risk of colectomy in pediatric-onset ulcerative colitis patients with an increased use of immunosuppressants and anti-TNF. However, the risk of disease extension and flare-related hospitalization increased.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Kengo Kanayama, Jun Kato, Wataru Shiratori, Ariki Nagashima, Yuki Ohta, Takashi Taida, Keiko Saito, Chihiro Goto, Satsuki Takahashi, Ryosuke Horio, Akane Kurosugi, Tsubasa Ishikawa, Tatsuya Kaneko, Naoki Akizue, Kenichiro Okimoto, Tomoaki Matsumura, Naoya Kato
Summary: This study found that selecting subsequent treatment based on the response to initial anti-tumor necrosis factor (TNF)alpha antibody (ATA) is feasible in refractory ulcerative colitis (UC) patients. Non-ATA may be suitable as subsequent biologics for UC patients regardless of the efficacy of the first ATA.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Guillaume Le Cosquer, Lena Capirchio, Pauline Riviere, Marie Armelle Denis, Florian Poullenot, Christophe Remue, Frank Zerbib, Daniel Leonard, Bertrand Celerier, Alex Kartheuser, David Laharie, Olivier Dewit
Summary: This study aimed to determine the trend of colectomy in ulcerative colitis (UC) by comparing colectomy indications and outcomes between 2000 and 2010 and 2011-2020. The results showed that the proportion of surgery for refractory UC significantly decreased compared to other surgical indications while surgical outcomes improved despite larger exposure to biologics.
DIGESTIVE AND LIVER DISEASE
(2023)
Article
Gastroenterology & Hepatology
Philip W. Jenkinson, Nikolas Plevris, Mathew Lyons, Rebecca Grant, James Fulforth, Kate Kirkwood, Ian D. Arnott, David Wilson, Angus J. M. Watson, Gareth-Rhys Jones, Charlie W. Lees
Summary: The study found that with the change in guidance, the use of maintenance biological therapy increased sharply, leading to a significant reduction in colectomy rates over the same time period.
COLORECTAL DISEASE
(2021)
Article
Gastroenterology & Hepatology
Abhishek Bhurwal, Carlos D. Minacapelli, Anish Patel, Hemant Mutneja, Akshay Goel, Ishani Shah, Vikas Bansal, Bhaumik Brahmbhatt, Kiron M. Das
Summary: This study revealed racial and geographical disparities in colectomy rates among hospitalized patients with UC after the introduction of anti-TNF therapy. African American and Hispanic patients had significantly lower colectomy rates compared to White patients, while the western regions of the United States had the highest colectomy rates. Further research is needed to understand the underlying social and biological factors contributing to these disparities.
INFLAMMATORY BOWEL DISEASES
(2022)
Article
Gastroenterology & Hepatology
Jeffrey A. Berinstein, Jessica L. Sheehan, Michael Dias, Elliot M. Berinstein, Calen A. Steiner, Laura A. Johnson, Randolph E. Regal, John I. Allen, Kelly C. Cushing, Ryan W. Stidham, Shrinivas Bishu, Jami A. R. Kinnucan, Shirley A. Cohen-Mekelburg, Akbar K. Waljee, Peter D. R. Higgins
Summary: The study suggests that tofacitinib with concomitant intravenous corticosteroids may reduce the risk of colectomy in ASUC patients, especially with a dosage of 10 mg three times daily. Rates of complications and steroid dependence were similar between the tofacitinib group and controls. Prospective trials are needed to further investigate the safety and optimal dosing of tofacitinib in ASUC patients.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Marina Liso, Giulio Verna, Elisabetta Cavalcanti, Stefania De Santis, Raffaele Armentano, Angela Tafaro, Antonio Lippolis, Pietro Campiglia, Antonio Gasbarrini, Mauro Mastronardi, Theresa Torres Pizarro, Fabio Cominelli, Loris Riccardo Lopetuso, Marcello Chieppa
Summary: This study provides new insights and alternative approaches to treat ulcerative colitis (UC) patients. It suggests that anti-interleukin (IL)1 strategies, such as anakinra, may be a more effective therapeutic option for primary nonresponders to anti-tumor necrosis factor (TNF) therapy.
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Matthieu Kouki, Benedicte Caron, Aurelie Malgras, Ahmet Ayav, Laurent Peyrin-Biroulet, Adeline Germain
Summary: This study is the first to show that patients with ulcerative colitis can regain their healthy weight after colectomy, which provides reassurance for patients before surgery.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
(2022)
Review
Gastroenterology & Hepatology
Nick Dai, Omar Haidar, Alan Askari, Jonathan P. Segal
Summary: This study aimed to understand the changing prevalence of colectomy in Ulcerative Colitis (UC) over time. The results showed that the overall colectomy rate has decreased over the past three decades. Biologics may have played a role in reducing the risk of colectomy, but the relative risk reduction is likely to be modest.
DIGESTIVE AND LIVER DISEASE
(2023)
Article
Gastroenterology & Hepatology
Brandon K. Chu, Frank I. Scott, Meenakshi Bewtra
Summary: This simulation study suggests that early incorporation of colectomy for patients medically refractory to infliximab and azathioprine combination therapy may lead to better quality of life for patients with steroid-dependent UC. This finding highlights the importance of a combined medical-surgical approach in the treatment of UC.
JOURNAL OF GASTROINTESTINAL SURGERY
(2021)
Article
Gastroenterology & Hepatology
Sun-Ho Lee, Margaret Walshe, Eun Hye Oh, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Tomer Greener, Adam Weizman, Mark S. Silverberg, Byong Duk Ye
Summary: The study suggests that changes in serum albumin levels within the first 2 weeks of anti-TNF treatment can predict primary nonresponse, endoscopic outcomes, time to colectomy, and anti-TNF failure in patients with UC. Early access to this biomarker may help identify patients at risk of treatment failure and guide early optimization of anti-TNF therapy.
INFLAMMATORY BOWEL DISEASES
(2021)
Article
Gastroenterology & Hepatology
David T. Rubin, Leonardo Salese, Mitchell Cohen, Paulo G. Kotze, John C. Woolcott, Chinyu Su, Rajiv Mundayat, Jerome Paulissen, Joana Torres, Millie D. Long
Summary: This study evaluated colectomy incidence rates and risk factors among patients with ulcerative colitis treated with tofacitinib. The results showed that colectomies were infrequent among patients receiving tofacitinib treatment, and all patients who underwent colectomy had additional risk factors.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
(2023)
Review
Gastroenterology & Hepatology
Edo H. J. Savelkoul, Pepijn W. A. Thomas, Lauranne A. A. P. Derikx, Nathan den Broeder, Tessa E. H. Romkens, Frank Hoentjen
Summary: Loss of response to infliximab or adalimumab in ulcerative colitis occurs frequently, with an annual rate of 10% for infliximab and 13% for adalimumab. Dose escalation rates were higher than loss of response, with 72% and 52% regaining clinical benefit for infliximab and adalimumab, respectively. Uniform definitions are needed for more robust evaluations.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Atsushi Kohyama, Kazuhiro Watanabe, Akira Sugita, Kitaro Futami, Hiroki Ikeuchi, Ken-ichi Takahashi, Yasuo Suzuki, Kouhei Fukushima
Summary: This study defined and investigated postoperative ulcerative colitis-related severe enteritis (UCRSE), with 0.8% of cases meeting the criteria. Major symptoms included massive intestinal bleeding, high-output stoma, and intestinal perforation. Some patients developed serious complications, required surgery or long-term maintenance therapy.
JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Medical Laboratory Technology
Jake S. Jasurda, Robert P. McCabe, Byron P. Vaughn
Summary: This study found that the average increase in serum ADA concentration after dose escalation from q14 to q7 days was 5.5 mcg/mL for patients with inflammatory bowel disease. Factors such as age, body mass index, and initial ADA concentration may influence the ability to achieve a target ADA concentration after dose escalation.
THERAPEUTIC DRUG MONITORING
(2021)
Article
Gastroenterology & Hepatology
William J. Sandborn, Julian Panes, Silvio Danese, Zaineb Sharafali, Azra Hassanali, Rhian Jacob-Moffatt, Christopher Eden, Marco Daperno, John F. Valentine, David Laharie, Carolina Baia, Raja Atreya, Remo Panaccione, Grazyna Rydzewska, Humberto Aguilar, Severine Vermeire
Summary: This study compared the safety and efficacy of two doses of Etrolizumab with placebo in patients with Crohn's disease. The results showed that during the maintenance phase, Etrolizumab significantly improved clinical remission and endoscopic improvement in patients with moderately to severely active Crohn's disease compared to placebo. However, there was no significant difference in the effects of Etrolizumab and placebo on clinical remission and endoscopic improvement during the induction phase.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2023)
Review
Gastroenterology & Hepatology
Javier P. Gisbert, Maria Jose Garcia, Maria Chaparro
Summary: For patients with steroid-refractory ASUC, both standard treatment (cyclosporine and infliximab) and newly developed agents (such as vedolizumab and ustekinumab) are effective options.
JOURNAL OF CROHNS & COLITIS
(2023)
Review
Gastroenterology & Hepatology
Javier P. Gisbert, Maria Chaparro
Summary: Infants exposed to biological drugs in utero have adequate serological responses to vaccines, and there are no relevant adverse events for non-live inactivated vaccines. Live-attenuated vaccines should be avoided in children with detectable levels of biological drugs. Breastfeeding by mothers treated with biologics is considered safe for infants, and the benefits of breastfeeding while receiving treatment and adhering to infant immunization programs outweigh any potential risk.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
Maria Jose Casanova, Oscar Nantes, Pilar Varela, Milagros Vela-Gonzalez, Montserrat Rivero, Olivia Sierra-Gabarda, Sabino Riestra, Manuel Barreiro-de Acosta, Maria del Mar Martin-Rodriguez, Carla Jerusalen Gargallo-Puyuelo, Cristina Reygosa, Roser Munoz, Irene Garcia de la Filia-Molina, Andrea Nunez-Ortiz, Lilyan Kolle, Margalida Calafat, Jose Maria Huguet, Eva Iglesias-Flores, Teresa de Jesus Martinez-Perez, Orencio Bosch, Jose Maria Duque-Alcorta, Santiago Frago-Larramona, Manuel Van Domselaar, Victor Manuel Gonzalez-Cosano, Luis Bujanda, Saioa Rubio, Alejo Mancebo, Beatriz Castro, Santiago Garcia-Lopez, Ruth de Francisco, Laura Nieto-Garcia, Viviana Laredo, Ana Gutierrez-Casbas, Francisco Mesonero, Eduardo Leo-Carnerero, Fiorella Canete, Lucia Ruiz, Beatriz Gros, Maria del Moral-Martinez, Cristina Rodriguez, Maria Chaparro, Javier P. Gisbert
Summary: This study compared the treatment persistence, clinical efficacy, and safety outcomes in inflammatory bowel disease patients who maintained the adalimumab originator versus those who switched to adalimumab biosimilar. The results showed that switching to adalimumab biosimilar did not show any significant differences in treatment persistence, clinical efficacy, and safety outcomes compared to maintaining the originator.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Biotechnology & Applied Microbiology
Bernd Bokemeyer, Tibor Hlavaty, Matthieu Allez, Pamela Selema, Shahrzad Moosavi, Mary Jane Cadatal, Heather Fowler, Markus Mueller, Katherine F. Liau, Javier P. Gisbert
Summary: This study investigated the use of CT-P13 in the treatment of patients with Crohn's disease and ulcerative colitis. The results showed that the safety information for CT-P13 was consistent with the known safety profile for IFX and did not alter the established benefit-risk profile of CT-P13.
EXPERT OPINION ON BIOLOGICAL THERAPY
(2023)
Article
Gastroenterology & Hepatology
Julian Panes, Severine R. Vermeire, Geert D'Haens, Silvio Danese, Fernando Magro, Maciej Nazar, Manuela Le Bars, Marjolein Lahaye, Lioudmila Ni, Ivana R. Bravata, Daniel Gaya, Laurent Peyrin-Biroulet, Axel Dignass
Summary: This study compared two treatment strategies for Crohn's disease patients and found that regardless of whether the treatment was "treat-to-target" or "standard of care", ustekinumab was effective in improving the health-related quality of life and work productivity of patients over a 2-year follow-up period.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL
(2023)
Article
Gastroenterology & Hepatology
Johan Burisch, Mirabella Zhao, Selwyn Odes, Peter De Cruz, Severine Vermeire, Charles N. Bernstein, Gilaad G. Kaplan, Dana Duricova, Dan Greenberg, Hans O. Melberg, Mamoru Watanabe, Hyeong Sik Ahn, Laura Targownik, Valerie E. H. Pittet, Vito Annese, K. T. Park, Konstantinos H. Katsanos, Marte L. Hoivik, Zeljko Krznaric, Maria Chaparro, Edward V. Loftus, Peter L. Lakatos, Javier P. Gisbert, Willem Bemelman, Bjorn Moum, Richard B. Gearry, Michael D. Kappelman, Ailsa Hart, Marieke J. Pierik, Jane M. Andrews, Siew C. Ng, Renata D'Inca, Pia Munkholm
Summary: The cost of caring for patients with inflammatory bowel disease (IBD) continues to increase worldwide due to the steady increase in prevalence, the chronic nature of the diseases, expensive treatments, intensive monitoring, and their impact on productivity. This Commission urges evaluation of cost increases against improved disease management and the need for data interoperability and big data approaches to assess effectiveness and cost-effectiveness. International collaborations and novel care models should be sought to enhance education and training for clinicians, patients, and policy makers.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2023)
Review
Pharmacology & Pharmacy
Javier P. Gisbert, Maria Chaparro
Summary: Surgery is not a cure for Crohn's disease, and postoperative recurrence is common. This article critically reviews the role of anti-TNF agents and new biologics in preventing and treating postoperative recurrence in Crohn's disease. Anti-TNFs have been shown to be the most effective agents in preventing and treating postoperative recurrence, while the effectiveness of vedolizumab and ustekinumab is still unclear.
Article
Gastroenterology & Hepatology
Angeles Perez-Aisa, Olga P. Nyssen, Alma Keco-Huerga, Luis Rodrigo, Alfredo J. Lucendo, Blas J. Gomez-Rodriguez, Juan Ortuno, Monica Perona, Jose Maria Huguet, Oscar Nunez, Luis Fernandez-Bermejo, Jesus Barrio, Angel Lanas, Eduardo Iyo, Pilar Mata Romero, Miguel Fernandez-Bermej, Barbara Gomez, Ana Garre, Judith Gomez-Camarero, Luis Javier Lamuela, Ana Campillo, Luisa de la Pena-Negro, Manuel Dominguez Cajal, Luis Bujanda, Diego Burgos-Santamaria, Fernando Bermejo, Victor Gonzalez-Carrera, Ramon Pajares, Pedro Almela Notari, Javier Tejedor-Tejada, Montserrat Planella, Itxaso Jimenez, Yolanda Arguedas Lazaro, Antonio Cuadrado-Lavin, Isabel Perez-Martinez, Edurne Amorena, Jesus M. Gonzalez-Santiago, Teresa Angueira, Virginia Flores, Samuel J. Martinez-Dominguez, Manuel Pabon-Carrasco, Benito Velayos, Alicia Algaba, Consuelo Ramirez, Enrique Alfaro Almajano, Manuel Castro-Fernandez, Noelia Alcaide, Patricia Sanz Segura, Anna Cano-Catala, Natalia Garcia-Morales, Leticia Moreira, Francis Megraud, Colm O'Morain, Xavier Calvet, Javier P. Gisbert
Summary: This study analyzed the effectiveness and safety of triple-dose administration of single capsule bismuth quadruple therapy (scBQT) in patients included in the European Registry on Helicobacter pylori Management. The results showed that the three times a day treatment schedule was more effective than the traditional four times a day schedule in terms of overall cure rates. There were no differences observed in treatment adherence or safety between the two regimens.
Meeting Abstract
Gastroenterology & Hepatology
M. Baldan-Martin, M. Azkargorta, I. Lloro, I. Soleto Fernandez, M. Orejudo, C. Ramirez, S. Garcia, J. Mercado, S. Riestra, M. Rivero, A. Gutierrez, I. Rodriguez-Lago, L. Fernandez-Salazar, D. Ceballos, J. M. Benitez, M. Aguas, I. Baston-Rey, F. Bermejo, M. J. Casanova, R. Lorente, Y. Ber, V. Royo, M. Esteve, F. Elortza, J. P. Gisbert, M. Chaparro
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
M. Baldan-Martin, I. Lloro, M. Azkargorta, C. Ramirez, I. Soleto Fernandez, M. Orejudo, S. Garcia, J. Mercado, C. H. Gordillo, S. Riestra, M. Rivero, A. Gutierrez, I. Rodriguez-Lago, L. Fernandez-Salazar, D. Ceballos, J. M. Benitez, M. Aguas, I. Baston-Rey, F. Bermejo, M. J. Casanova, R. Lorente, Y. Ber, V. Royo, M. Esteve, F. Elortza, J. P. Gisbert, M. Chaparro
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
I. Guerra Marina, F. Barros, F. Mesonero, R. de Francisco, F. Canete, J. M. Benitez, B. Sicilia, M. D. Martin Arranz, L. de Castro, A. Y. Carbajo, A. Gutierrez, M. Calvo, M. J. Casanova, C. Gonzalez-Munoza, M. Miguel, E. Alfambra, M. Rivero, A. J. Lucendo, C. A. Tardillo, P. Almela, L. Bujanda, M. Van Domselaar, L. Ramos, M. Fernandez Sanchez, E. Hinojosa, C. Verdejo, A. Gimenez, M. Piqueras, I. Rodriguez-Lago, N. Mancenido, J. L. Perez Calle, M. D. P. Moreno, P. G. Delgado, B. Antolin, P. Ramirez de la Piscina, F. Bermejo, A. Carracedo, E. Domenech, J. P. Gisbert
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
I. Guerra Marina, F. Barros, M. Chaparro, J. M. Benitez, M. D. Martin Arranz, R. de Francisco, M. Piqueras, L. de Castro, A. Y. Carbajo, F. Bermejo, M. Minguez, A. Gutierrez, F. Mesonero, F. Canete, C. Gonzalez-Munoza, M. Calvo, B. Sicilia, E. Alfambra, C. A. Tardillo, M. Rivero, A. J. Lucendo, L. Bujanda, M. Van Domselaar, P. Almela, L. Ramos, M. Fernandez Sanchez, E. Hinojosa, C. Verdejo, A. Gimenez, I. Rodriguez-Lago, N. Mancenido, J. L. Perez Calle, M. D. P. Moreno, P. G. Delgado-Guillena, B. Antolin, P. Ramirez de la Piscina, M. J. Casanova, A. Carracedo, E. Domenech, J. P. Gisbert
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
A. B. Julian, D. Casas-Deza, R. Vicente-Lidon, B. Beltran, E. Domenech, A. Gutierrez-Casbas, M. Manosa, Y. Zabana, E. Caudevilla-Biota, P. Corsino-Roche, E. Sierra-Moros, L. E. Franco-Fobe, S. Pina-Echevarria, E. Garcia-Gonzalez, E. Alfambra, C. Gargallo-Pueyo, B. Sicilia, L. Arias, M. J. Alcala-Escriche, L. Madero-Velazquez, R. Ferreiro-Iglesias, A. Palmero-Perez, M. Calafat, S. Rubio-Iturria, I. Moraleja-Yudego, Y. Ber-Nieto, S. Garcia-Mateo, J. P. Gisbert, M. Barreiro-de Acosta, S. Garcia-Lopez
JOURNAL OF CROHNS & COLITIS
(2023)
Meeting Abstract
Gastroenterology & Hepatology
I. Guerra Marina, L. Bujanda, M. Manosa, I. Perez-Martinez, M. J. Casanova, L. de la Pena, M. de Benito, M. Rivero, P. Varela, L. Bernal, A. C. Franco, Y. Ber, M. Piqueras, C. Tardillo, A. Ponferrada, S. Olivares, A. J. Lucendo, P. Gilabert, M. Sierra Ausin, M. Bellart, A. Herrarte, M. Calafat, R. de Francisco, J. P. Gisbert, J. Guardiola, E. Domenech, F. Bermejo
JOURNAL OF CROHNS & COLITIS
(2023)